Clinical trials: Nonsmall Cell Lung Cancer Stage III
Lung Cancer
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:
A retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (HCRU) for patients diagnosed with primary…
- Trial name
- REVEAL (NCT04836975)
- Where
- Saudi Arabia
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer Stage III
Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well.
- Trial name
- NCT02053285
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rush University Medical Center
Oncology
A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer cOnsidered Higher Risk of Complications From Surgical Resection
Stage I non-small cell lung cancer (NSCLC) is curable and surgery is considered the standard of care for fit, good performance status patients.
- Trial name
- SABRTOOTHv1 (NCT02629458)
- Testing
- Treatment by Surgical resection, Stereotactic Ablative Radiotherapy (SABR)
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Breast Cancer, Colorectal Cancer
Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer
RATIONALE: Collecting information over time about patients' and health care providers' understanding of pain and fatigue and providing education about pain and fatigue management may improve quality of life.
- Conditions
- Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer
- Trial name
- NCT00900835
- Testing
- educational intervention, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- City of Hope Medical Center
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer Stage III
Accelerated Radio-Immunotherapy for Lung Cancer
Radiotherapy (RT), at a total dose of 60-66 Gy over 6 weeks, combined with platinum-based chemotherapy, is the standard of care for stage III Non-Small Cell Lung Cancers (NSCLC) patients with unresectable or inoperable disease.
- Trial name
- AIRING (NCT04577638)
- Testing
- Nivolumab and Intensity Modulated Radiotherapy (IMRT)
- Where
- 5 sites in France
- Volunteers
- 8 people
- Sponsor
- Center Eugene Marquis
Non Small Cell Lung Cancer
Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study
This study is for patients having a course of chest radiotherapy treatment after receiving chemotherapy for the treatment of non-small cell lung cancer.
- Trial name
- Isotoxic-IMRT (NCT01836692)
- Testing
- Intensity Modulated Radiotherapy treatment
- Where
- 7 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Prof Corinne Faivre-Finn
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent…
- Trial name
- NCT00806819
- Testing
- Nintedanib (BIBF1120), Pemetrexed, B12
- Where
- 163 sites in United States, Argentina and 30 more
- Volunteers
- 718 people
- Sponsor
- Boehringer Ingelheim
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL)…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02706392
- Testing
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Carcinoma, Non-Small-Cell Lung
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a…
- Trial name
- GeoMETry-III (NCT04427072)
- Testing
- Capmatinib, Docetaxel
- Where
- 43 sites in Belgium, Brazil and 16 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01210053
- Testing
- malate Given orally
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Third Military Medical University
Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
This phase III trial studies how well a telehealth self-management program works in improving survivorship care and outcomes in stage I-III non-small cell lung cancer or colorectal cancer survivors.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8
- Trial name
- NCT04428905
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Survivorship Care Plan
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- City of Hope Medical Center
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III
Her2-positive Lung Cancer Treated With Dedicated Drug
HER2 (erbB-2/neu) is a member of the erbB receptor tyrosine kinase family. ERBB2 gene which encodes human epidermal growth factor 2 (HER2) is a major proliferative driver activating downstream signaling through PI3K-AKT and…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III, HER2 Gene Mutation
- Trial name
- R2D2 (NCT03845270)
- Testing
- pertuzumab + trastuzumab + docetaxel
- Where
- 18 sites in France
- Volunteers
- 46 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer
Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003037
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281827
- Testing
- carboplatin, gemcitabine hydrochloride, thalidomide
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non Small Cell Lung Cancer (NSCLC), Radical Treatment
Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC
For patients with stage III non-small cell lung cancer, which is radically treated, we will investigate whether prophylactic cranial irradiation (PCI) should become standard of care to prevent brain metastases.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Radical Treatment, Stage III Non-Small Cell Lung Cancer
- Trial name
- NVALT11 (NCT01282437)
- Testing
- Prophylactic Cranial Irradiation
- Where
- 9 sites in Netherlands
- Volunteers
- 315 people
- Sponsor
- Maastricht Radiation Oncology
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
This study is a prospective, multi-center, randomized, open-ended, double-arm clinical study. All eligible patients were randomly assigned to DEB-BACE combined with PD-1 inhibitor (Sindilizumab) treatment group (test group) and…
- Trial name
- NCT05248022
- Testing
- Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Non Small Cell Lung Cancer
Performance Status During Treatment With Pemetrexed in Patients With NSCLC
The primary research objective of this observational study in pretreated patients with NSCLC of Stage IIIa/b or Stage IV is to evaluate patients' Karnofsky Index (KI) after the second cycle of second-line treatment with single…
- Trial name
- PERFORMANCE (NCT00540241)
- Testing
- Pemetrexed
- Where
- Germany
- Volunteers
- 542 people
- Sponsor
- Eli Lilly and Company